Does BPC-157 heal tendons and ligaments in people?

Where the claim comes from: rat injury models

The tendon claim traces back to animal surgery models. In a 2003 study, researchers cut the Achilles tendon in rats and gave BPC-157 or saline. Treated rats did better on load-to-failure and stiffness tests, walking-function scores, and tissue examination, and the gap in the tendon was smaller. The authors described full restoration of tendon integrity in the treated animals.

A 2010 rat study cut the medial collateral ligament of the knee in rats. BPC-157 given by injection, in drinking water, or as a cream on the injury site was associated with better function, biomechanics and tissue appearance than controls. These are well-designed animal experiments, but they show what happens in rats after a clean surgical cut. That is a very different situation from a chronic tendon problem or a partial ligament tear in a person.

Sources: PubMed 14554208 · PubMed 20225319

What the cell studies suggest about mechanism

In cultured rat tendon fibroblasts, BPC-157 did not directly speed up cell division. It did help the cells survive oxidative stress, and it increased their migration and spreading in a dose-dependent way. The authors linked these effects to activation of the FAK-paxillin signalling pathway.

Other lab work has reported that BPC-157 raises growth hormone receptor expression in tendon fibroblasts. A 2025 systematic review summarised the proposed mechanisms as effects on growth signalling, new blood vessel formation and inflammatory cytokines. A plausible mechanism makes the idea worth testing, but it does not show that the peptide works in a human tendon.

Sources: PubMed 21030672 · PubMed 40756949

What has actually been studied in people

The only human report touching on joints is a 2021 retrospective chart review from a single clinic. Of 17 patients who had BPC-157 (alone or with thymosin beta-4) injected into the knee, 16 were reached by phone. Of the 12 who received BPC-157 alone, 11 said their pain improved significantly. No validated function or quality-of-life scales were used, there was no imaging, the follow-up time varied, and there was no control group. Knee pain also had several different causes in this group, so the study cannot show that any tendon or ligament healed. A later systematic review summarised the same report as 7 of 12 patients having relief for more than 6 months, which shows how easily such a thin dataset gets reported in different ways.

The other two human reports are not about tendons. One gave BPC-157 by intravenous infusion to 2 adults who had already used it, and found no change in the blood markers that were tested. The other injected it into the bladder wall of 12 women with interstitial cystitis, with no comparison group. A 2026 pharmaceutics review estimated that all available clinical data come from fewer than 30 people across three uncontrolled pilot studies.

Sources: PubMed 34324435 · PubMed 40131143 · PubMed 39325560 · PubMed 42198317

What independent reviews conclude

A 2025 systematic review in orthopaedic sports medicine screened 544 records and included 36 studies: 35 were preclinical and only 1 was clinical. It found no clinical safety data and noted that harms could arise from unregulated manufacturing or contamination. A 2025 narrative review reached the same view, calling human data extremely limited and saying BPC-157 should be considered investigational until well-designed trials exist.

A 2026 scoping review in The American Journal of Sports Medicine found that 67% of the publications it identified on popular recovery peptides used animal models. It concluded that the claimed musculoskeletal benefits are not backed by current human trials. A 2026 primer for orthopaedic surgeons likewise described the tendon and muscle findings for BPC-157 as largely unvalidated in humans.

Sources: PubMed 40756949 · PubMed 40789979 · PubMed 42578445 · PubMed 41476424

What is missing, and what is coming

No randomized, placebo-controlled trial of BPC-157 for a tendon or ligament injury has published results. The 2026 pharmaceutics review also notes that there is no validated pharmaceutical formulation and that no Phase II trial has been completed. In animals, the peptide's half-life in plasma is under 30 minutes, and its human pharmacokinetics are poorly characterized.

ClinicalTrials.gov lists a randomized, quadruple-blind, placebo-controlled Phase 2 trial in grade II hamstring strains (estimated 120 participants, recruiting). Its outcomes are return to sport and MRI injury volume. A smaller randomized trial after rotator cuff repair (estimated 30 participants) is listed as not yet recruiting. Until results like these are published, the claim remains unproven.

Sources: PubMed 42198317 · clinicaltrials.gov · clinicaltrials.gov

Safety and regulatory context

BPC-157 is not an FDA-approved drug. On its page about bulk drug substances that may pose significant safety risks in compounding, the FDA lists BPC-157 among substances that were previously in category 2 and whose nominations were withdrawn. The agency says compounded BPC-157 may pose a risk of immune reactions for some routes, that impurities and characterization are complex, and that it has too little safety information to know whether the drug would cause harm in humans.

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding BPC-157 to the 503A bulks list. The use under review was ulcerative colitis, not tendon or ligament injury. FDA staff had recommended against listing it, citing a lack of evidence of effectiveness for that use. The vote is advisory and is not a drug approval. Sports-medicine reviews also note that BPC-157 is banned in professional sport. Athletes should check the current WADA Prohibited List.

Sources: fda.gov · fda.gov · raps.org · PubMed 40756949 · wada-ama.org

Profiles

BPC-157 profile →

References

1. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res · 2003 · PMID 14554208
2. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res · 2010 · PMID 20225319
3. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985) · 2011 · PMID 21030672
4. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J · 2025 · PMID 40756949
5. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med · 2021 · PMID 34324435
6. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med · 2025 · PMID 40131143
7. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med · 2024 · PMID 39325560
8. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics · 2026 · PMID 42198317
9. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med · 2025 · PMID 40789979
10. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med · 2026 · PMID 42578445
11. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med · 2026 · PMID 41476424

Other sources

• https://clinicaltrials.gov/study/NCT07437547
• https://clinicaltrials.gov/study/NCT07803250
• https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
• https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
• https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html
• https://www.wada-ama.org/en/prohibited-list

These are original summaries of published research, written with AI assistance and checked against the cited sources. They are not medical advice and have not been reviewed by a clinician. Every PubMed reference was checked against PubMed's record for title, year and journal. All claim checks · Editorial standards